Latest news with #PatientView
Malaysian Reserve
3 days ago
- Business
- Malaysian Reserve
Servier Ranked Among Top Companies Across Several Categories in 2024 PatientView Corporate Reputation of Pharma Survey
Servier U.S. ranked #1 across several categories U.S. recognition follows last month's announcement that Servier made the top ten list of organizations evaluated by PatientView globally BOSTON, May 28, 2025 /PRNewswire/ — Servier today announced that the company was ranked among the top companies across several categories in PatientView's 2024 Corporate Reputation of Pharma in the U.S. survey. This annual survey captures insights from more than 350 patient organizations reflecting their firsthand experiences, perceptions and familiarity with pharmaceutical companies. This ranking comes on the heels of PatientView's Global Reputation of Pharma Survey – where Servier earned a spot in the Top 10 of pharmaceutical company reputations among patient organizations. This marked the first time in the Top 10 globally, reinforcing our ever-increasing commitment to patients and the organizations that represent them. 'Being recognized at the top of PatientView's annual rankings is not just an honor, it's a meaningful reflection of our continued commitment to listening to patients, collaborating closely with patient advocates, and delivering solutions that truly meet needs,' said Nicolas Garnier, Chief Patient Officer, Servier. 'This recognition is a reflection of our deep, ongoing commitment to putting patients first and acknowledging the essential role they play in shaping our work at every stage. This kind of external validation reinforces that we are listening, learning, and taking the right actions to truly support patients and the communities that represent them.' U.S. patient organizations also ranked Servier in the top two across all categories and first in several categories: Transparency on Data, Integrity, Beyond the Pill, Engagement in R&D. Globally, Servier was also ranked among the top 10 companies – underscoring the company's growing reputation and meaningful impact on patients worldwide. 'At Servier, engaging meaningfully with patient organizations and ensuring access to medicines are fundamental priorities,' said Wendy Poage, Vice President of the Patient Office at Servier. 'We're honored to be recognized in the Patient View report for our integrity and commitment to delivering support that goes beyond the pill. This kind of external validation reinforces that we are listening, learning, and taking the right actions to truly support patients and the communities that represent them.' For more information on Servier Pharmaceuticals patient support services, please visit and About the Corporate Reputation of Pharma Survey 2024 'Corporate Reputation of Pharma' survey of patient groups worldwide was conducted December 2024 to March 2025 and answered by 372 US patient groups, representing over 13 million US patients during the past year. The PatientView annual Corporate Reputation of Pharma survey gives patient-advocacy groups an opportunity to comment on, and assess, the pharma industry's performance. Companies are ranked against their peers. The survey results reinforce the dedication, commitment and hard work companies invest internally to ensure engagement with patients and advocacy groups is reflective of the patients they serve. About Servier Servier is a global pharmaceutical group governed by a nonprofit foundation, committed to making a meaningful social impact for patients and contributing to a sustainable world. Its unique governance model ensures its independence, while supporting long-term innovation, with 100% of its profits reinvested in the Group's development. As a world leader in hypertension and venous diseases and major player in cardiometabolism, Servier drives transformative innovation to support patients with chronic conditions and improve their day-to-day lives through a holistic approach, which includes making patient adherence and control a priority across the globe. Its ambition is to become a leading player in rare cancers, which is why the Group invests heavily in oncology, allocating close to 70% of its R&D budget to this field. By leveraging precision medicine, Servier develops therapies that are more targeted and more effective. Bolstered by its success in oncology, Servier has expanded into neurology, a key driver of future growth. The Group is focused on a select number of neurodegenerative diseases, where accurate patient profiling enables targeted therapeutic responses through precision medicine. To open up wider access to high-quality, affordable care, Servier also offers an extensive range of generic medicines, building on well-established brands in France, Eastern Europe, and Brazil. In all its activities, and at every stage of the medicine life cycle, the Group integrates the patient's voice. Headquartered in France, Servier operates in around 140 countries. In 2023-2024, the Group, which employs over 22,000 people worldwide, achieved revenues of €5.9 billion. More information on our website : Follow us on social media : LinkedIn, Facebook, Twitter, Instagram Media Contact: Sara Noonan
Yahoo
3 days ago
- Business
- Yahoo
Servier Ranked Among Top Companies Across Several Categories in 2024 PatientView Corporate Reputation of Pharma Survey
Servier U.S. ranked #1 across several categories U.S. recognition follows last month's announcement that Servier made the top ten list of organizations evaluated by PatientView globally BOSTON, May 28, 2025 /PRNewswire/ -- Servier today announced that the company was ranked among the top companies across several categories in PatientView's 2024 Corporate Reputation of Pharma in the U.S. survey. This annual survey captures insights from more than 350 patient organizations reflecting their firsthand experiences, perceptions and familiarity with pharmaceutical companies. This ranking comes on the heels of PatientView's Global Reputation of Pharma Survey – where Servier earned a spot in the Top 10 of pharmaceutical company reputations among patient organizations. This marked the first time in the Top 10 globally, reinforcing our ever-increasing commitment to patients and the organizations that represent them. "Being recognized at the top of PatientView's annual rankings is not just an honor, it's a meaningful reflection of our continued commitment to listening to patients, collaborating closely with patient advocates, and delivering solutions that truly meet needs," said Nicolas Garnier, Chief Patient Officer, Servier. "This recognition is a reflection of our deep, ongoing commitment to putting patients first and acknowledging the essential role they play in shaping our work at every stage. This kind of external validation reinforces that we are listening, learning, and taking the right actions to truly support patients and the communities that represent them." U.S. patient organizations also ranked Servier in the top two across all categories and first in several categories: Transparency on Data, Integrity, Beyond the Pill, Engagement in R&D. Globally, Servier was also ranked among the top 10 companies - underscoring the company's growing reputation and meaningful impact on patients worldwide. "At Servier, engaging meaningfully with patient organizations and ensuring access to medicines are fundamental priorities," said Wendy Poage, Vice President of the Patient Office at Servier. "We're honored to be recognized in the Patient View report for our integrity and commitment to delivering support that goes beyond the pill. This kind of external validation reinforces that we are listening, learning, and taking the right actions to truly support patients and the communities that represent them." For more information on Servier Pharmaceuticals patient support services, please visit and About the Corporate Reputation of Pharma Survey 2024 'Corporate Reputation of Pharma' survey of patient groups worldwide was conducted December 2024 to March 2025 and answered by 372 US patient groups, representing over 13 million US patients during the past year. The PatientView annual Corporate Reputation of Pharma survey gives patient-advocacy groups an opportunity to comment on, and assess, the pharma industry's performance. Companies are ranked against their peers. The survey results reinforce the dedication, commitment and hard work companies invest internally to ensure engagement with patients and advocacy groups is reflective of the patients they serve. About Servier Servier is a global pharmaceutical group governed by a nonprofit foundation, committed to making a meaningful social impact for patients and contributing to a sustainable world. Its unique governance model ensures its independence, while supporting long-term innovation, with 100% of its profits reinvested in the Group's development. As a world leader in hypertension and venous diseases and major player in cardiometabolism, Servier drives transformative innovation to support patients with chronic conditions and improve their day-to-day lives through a holistic approach, which includes making patient adherence and control a priority across the globe. Its ambition is to become a leading player in rare cancers, which is why the Group invests heavily in oncology, allocating close to 70% of its R&D budget to this field. By leveraging precision medicine, Servier develops therapies that are more targeted and more effective. Bolstered by its success in oncology, Servier has expanded into neurology, a key driver of future growth. The Group is focused on a select number of neurodegenerative diseases, where accurate patient profiling enables targeted therapeutic responses through precision medicine. To open up wider access to high-quality, affordable care, Servier also offers an extensive range of generic medicines, building on well-established brands in France, Eastern Europe, and Brazil. In all its activities, and at every stage of the medicine life cycle, the Group integrates the patient's voice. Headquartered in France, Servier operates in around 140 countries. In 2023-2024, the Group, which employs over 22,000 people worldwide, achieved revenues of €5.9 billion. More information on our website : Follow us on social media : LinkedIn, Facebook, Twitter, Instagram Media Contact: Sara Noonan View original content to download multimedia: SOURCE Servier Pharmaceuticals Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
15-05-2025
- Business
- Business Wire
VideaHealth Launches VideaInsights to Help Dental Leaders Elevate Care and Scale Smarter
BOSTON--(BUSINESS WIRE)-- VideaHealth, a leader in AI-powered dental solutions, today announced the launch of VideaInsights, an advanced dental analytics solution designed to help Dental Service Organizations (DSOs) and multi-location practice owners elevate care standards, coach with confidence, and scale smarter. VideaInsights provides targeted, AI-driven visibility into clinical behavior at the provider and practice levels. It surfaces up to $100,000 additional treatment opportunities per practice per month and helps dental organizations reduce the need for in-person mentorship visits by up to 50%. Rather than relying solely on production data or sporadic in-person audits, dental leaders can now lead with insight, not oversight, empowering mentorship, supporting growth, and strengthening patient outcomes. 'Dental organizations today face tremendous pressure to grow efficiently while maintaining consistent, high-quality care across every location,' said Florian Hillen, CEO of VideaHealth. 'VideaInsights offers a smarter way forward. It brings clear, actionable visibility into clinical behavior so leaders can elevate standards, scale mentorship, and drive real business value without micromanagement.' With VideaInsights, organizations can: Identify treatment and task completion gaps at both the provider and practice levels. Benchmark clinical performance by comparing care delivered against AI-identified opportunities to highlight coaching needs. Support coaching conversations with mentor-friendly visuals, including side-by-side full-mouth X-rays (FMXs). Spot trends proactively, addressing clinical gaps and identifying high-performing patterns early rather than waiting for quarter-end reviews. Until now, most DSOs and multi-location practices have relied on production output alone to evaluate clinical performance. VideaInsights addresses this by surfacing both delivered care and potential opportunities, helping leaders focus coaching on the 'how,' not just the 'how much.' Early adopters, including Gen4 Dental Partners, have already started integrating VideaInsights into their operations. 'VideaInsights gives us the ability to clearly identify dental issues and track how we're addressing them. This level of insight empowers our clinicians to detect concerns in real time and use tools like Videa's Patient View to communicate findings with clarity and confidence. These features improve diagnostic accuracy and enable more timely scheduling, helping minimize patient complications,' said Dr. Mitch Ellingson, Chief Clinical Officer at Gen4 Dental Partners. VideaInsights is part of the newly expanded VideaAI platform, a comprehensive Dental AI Assistant designed to help practices elevate care standards, improve productivity, and drive real business value across clinical diagnostics, workflow management, and analytics. About VideaHealth VideaHealth is transforming dentistry with AI-powered solutions that help practices elevate care standards, improve productivity, and drive real business value. VideaAI, a comprehensive Dental AI Assistant, supports every aspect of dental care, from diagnostics and workflows to analytics and revenue optimization. Used by more than 50,000 clinicians across 50+ leading DSOs, VideaHealth's FDA-cleared AI analyzes over 500 million X-rays annually, delivering trusted insights that power consistent, high-quality care. Headquartered in Boston and backed by leading investors, VideaHealth is advancing the future of dental care through responsible and real-world AI. Learn more at
Associated Press
10-04-2025
- Health
- Associated Press
PatientView Ranks Gilead 'Best' at ESG
At Gilead, putting people first is central to all we do. That's why we're proud to be recognized as a responsible company by patient advocacy groups representing more than 70 countries. In a new report from UK-based PatientView, we were ranked 'best' at ESG by patient groups who work with us. About Gilead SciencesGilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
